Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis

por Ribero, Simone, Licciardello, Matteo, Quaglino, Pietro, Dapavo, Paolo
Publicado 2019

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series

por REPETTO, Federica, BURZI, Lorenza, RIBERO, Simone, QUAGLINO, Pietro, DAPAVO, Paolo
Publicado 2022

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs

por Burzi, Lorenza, Repetto, Federica, Ribero, Simone, Mastorino, Luca, Quaglino, Pietro, Dapavo, Paolo
Publicado 2022

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study

por REPETTO, Federica, ROCCUZZO, Gabriele, BURZI, Lorenza, MASTORINO, Luca, DAPAVO, Paolo, QUAGLINO, Pietro, RIBERO, Simone
Publicado 2023

The Skin Microbiome and Its Role in Psoriasis: A Review

por Celoria, Valentina, Rosset, Francois, Pala, Valentina, Dapavo, Paolo, Ribero, Simone, Quaglino, Pietro, Mastorino, Luca
Publicado 2023

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

por Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Publicado 2022

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?

por Roccuzzo, Gabriele, Rozzo, Giulia, Burzi, Lorenza, Repetto, Federica, Dapavo, Paolo, Ribero, Simone, Quaglino, Pietro
Publicado 2022

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?

por Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Siliquini, Niccolò, Avallone, Gianluca, Rubatto, Marco, Quaglino, Pietro, Ribero, Simone
Publicado 2022

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study

por Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Zenone, Mattia, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Publicado 2022

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy

por MASTORINO, Luca, DAPAVO, Paolo, TRUNFIO, Mattia, AVALLONE, Gianluca, RUBATTO, Marco, CALCAGNO, Andrea, RIBERO, Simone, QUAGLINO, Pietro
Publicado 2022

Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies

por Ricci, Alessia Andrea, Dapavo, Paolo, Mastorino, Luca, Roccuzzo, Gabriele, Wolff, Samanta, Ribero, Simone, Cassoni, Paola, Senetta, Rebecca, Quaglino, Pietro
Publicado 2023

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population

por Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Siliquini, Niccolò, Avallone, Gianluca, Rubatto, Marco, Merli, Martina, Agostini, Andrea, Ribero, Simone, Quaglino, Pietro
Publicado 2022

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient

por Quaglino, Pietro, Fava, Paolo, Cariti, Caterina, Ortoncelli, Michela, Aimetti, Mario, Milan, Alberto, Dapavo, Paolo, Tonella, Luca, Ribero, Simone, Fierro, Maria Teresa
Publicado 2021

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

por Mastorino, Luca, Susca, Sara, Megna, Matteo, Siliquini, Niccolò, Quaglino, Pietro, Ortoncelli, Michela, Avallone, Gianluca, Rubatto, Marco, Fabbrocini, Gabriella, Dapavo, Paolo, Ribero, Simone
Publicado 2022

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience

por Gisondi, Paolo, Piaserico, Stefano, Naldi, Luigi, Dapavo, Paolo, Conti, Andrea, Malagoli, Piergiorgio, Marzano, Angelo Valerio, Bardazzi, Federico, Gasperini, Massimo, Cazzaniga, Simone, Costanzo, Antonio
Publicado 2021

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study

por Avallone, Gianluca, Maronese, Carlo Alberto, Murgia, Giulia, Carrera, Carlo Giovanni, Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Alberti-Violetti, Silvia, Quaglino, Pietro, Ribero, Simone, Marzano, Angelo Valerio
Publicado 2023

Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study

por Rossi, Oliviero, Piccirillo, Angelo, Iemoli, Enrico, Patrizi, Annalisa, Stingeni, Luca, Calvieri, Stefano, Gola, Massimo, Dapavo, Paolo, Cristaudo, Antonio, Zichichi, Leonardo, Losappio, Laura, Saccheri, Fabiana, Pastorello, Elide Anna
Publicado 2020

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

por BORRONI, Riccardo G., MALAGOLI, Piergiorgio, GARGIULO, Luigi, VALENTI, Mario, PAVIA, Giulia, FACHERIS, Paola, MORENGHI, Emanuela, DI CORTERANZO, Isotta Giunipero, NARCISI, Alessandra, ORTONCELLI, Michela, DAPAVO, Paolo, COSTANZO, Antonio
Publicado 2021

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study

por GNESOTTO, Laura, MIOSO, Guido, BARDAZZI, Federico, FILIPPI, Federica, DI LERNIA, Vito, MOTOLESE, Alberto, DI NUZZO, Sergio, CONTI, Andrea, ARGINELLI, Federica, CORAZZA, Monica, ODORICI, Giulia, BORGHI, Alessandro, GISONDI, Paolo, NALDI, Luigi, DAPAVO, Paolo, PARODI, Aurora, BURLANDO, Martina, PIASERICO, Stefano
Publicado 2023

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

por Pellegrini, Cristina, Esposito, Maria, Rossi, Ernesto, Gisondi, Paolo, Piaserico, Stefano, Dapavo, Paolo, Conti, Andrea, Gambardella, Alessio, Burlando, Martina, Narcisi, Alessandra, Offidani, Annamaria, Balestri, Riccardo, Bardazzi, Federico, Prignano, Francesca, Mugheddu, Cristina, Romanelli, Marco, Malara, Giovanna, Schinzari, Giovanni, Fargnoli, Maria Concetta
Publicado 2022